Case 10-2009: A 23-year-old woman with an abnormal papanicolaou smear

New England Journal of Medicine

Volumn 360, Issue 13, 2009, Pages 1337-

  Goldstein, Mark A ^a,b   Goodman, Annekathryn ^a,b   Del Carmen, Marcela G ^a,b   Wilbur, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; WART VIRUS VACCINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER SCREENING; CANCER SURGERY; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; ORAL CONTRACEPTION; PAPANICOLAOU TEST; PATIENT COUNSELING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SMOKING; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VERRUCA VULGARIS; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; PATHOLOGY; RISK FACTOR; SEXUALITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY; VIRUS INFECTION;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES, VIRAL; VAGINAL SMEARS; YOUNG ADULT;

EID: 63249083596     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc0810837     Document Type: Article

References (36)

1. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004;36:6-10.
2. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338: 423-8.
3. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intra- epithelial lesion development in young females. JAMA 2001;285:2995-3002.
4. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-26. [Erratum, Am J Epidemiol 2003;157:858.]
5. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645-54.
6. Moscicki AB. HPV infections in adolescents. Dis Markers 2007;23:229-34.
7. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24:Suppl 3:S3/42-S3/51.
8. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008;197:279-82.
9. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004;190:37-45.
10. Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008;148:493-500.
11. ACOG Committee on Practice Bulletins. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists: number 45, August 2003: cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol 2003;102:417-27.
12. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neopla- sia and cancer. CA Cancer J Clin 2002;52: 342-62.
13. Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. Rockville, MD: Agency for Healthcare Research and Quality, 2008.
14. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004;364:1678-83.
15. Wright JD, Davila RM, Pinto KR, et al. Cervical dysplasia in adolescents. Obstet Gynecol 2005;106:115-20.
16. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-55.
17. Huang YK, You SL, Yuan CC, et al. Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening. Br J Cancer 2008;98:863-9.
18. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
19. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2007;2:15.
20. Rodriguez AC, Burk R, Herrero R, et al. The natural history of human papillomavirus infection and cervical intraepi- thelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis 2007; 34:494-502.
21. Moscicki AB, Ma Y, Wibbelsman C, et al. Risks for cervical intraepithelial neoplasia 3 among adolescents and young women with abnormal cytology. Obstet Gynecol 2008;112:1335-42.
22. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a metaanalysis. Obstet Gynecol 1998;92:727-35.
23. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92.
24. MacLean AB. Acetowhite epithelium. Gynecol Oncol 2004;95:691-4.
25. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-73.
26. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 2007;107:Suppl 1:S19-S23.
27. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006;24:Suppl 3:S3/106-S3/113.
28. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into viruslike particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992;89:12180-4.
29. Gardasil prescribing information. Whitehouse Station, NJ: Merck, 2007 (package insert).
30. Gall SATJ, Naud P. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. Presented at the Annual American Association for Cancer Research Meeting, Los Angeles, April 14-18, 2007. abstract.
31. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
32. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
33. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70. [Erratum, Lancet 2007;370: 1414.]
34. The FUTURE II Study Group. Quadrivalent vaccine against human papilloma- virus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
35. Ault KA, FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
36. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.